Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo

Pharmacology Biochemistry and Behavior

Volumn 57, Issue 1-2, 1997, Pages 231-241

  Briggs, Clark A ^a   Anderson, David J ^a   Brioni, Jorge D ^a   Buccafusco, Jerry J ^b,c   Buckley, Michael J ^a   Campbell, Jeffrey E ^b,c   Decker, Michael W ^a   Donnelly Roberts, Diana ^a   Elliott, Richard L ^a   Gopalakrishnan, Murali ^a   Holladay, Mark W ^a   Hui, Yu Hua ^a   Jackson, William J ^b   Kim, David J B ^a   Marsh, Kennan C ^a   O'Neill, Alyssa ^a   Prendergast, Mark A ^b   Ryther, Keith B ^a   Sullivan, James P ^a   Arneric, Stephen P ^a  

^a ABBOTT LABORATORIES   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anabaseine; Anxiety; GTS 21; Human; Learning; Monkey; Mouse; Nicotine; Nicotinic receptors; Pharmacokinetics; Rat; Toxicity

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ALPHA BUNGAROTOXIN; BENZYLIDENE DERIVATIVE; CYTISINE; DIHYDRO BETA ERYTHROIDINE; LIGAND; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; OXOTREMORINE M; RUBIDIUM CHLORIDE RB 86;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN MEMBRANE; CONTROLLED STUDY; DOG; DOPAMINE RELEASE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEARNING; MALE; MEMBRANE BINDING; MEMORY; MONKEY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TASK PERFORMANCE;

ANIMALS; ANTI-ANXIETY AGENTS; BEHAVIOR, ANIMAL; BENZYLIDENE COMPOUNDS; CLONING, MOLECULAR; DOGS; GANGLIA; HUMANS; MACACA FASCICULARIS; MACACA NEMESTRINA; MALE; MICE; MICE, INBRED STRAINS; NEURONS; NICOTINIC AGONISTS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, NICOTINIC;

ANIMALIA; CANIS FAMILIARIS; RODENTIA;

EID: 0031003185     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(96)00354-1     Document Type: Article

References (51)

1. Albuquerque, E. X.; Pereira, E. F. R.; Castro, N. G.; Alkondon, M.: Neuronal nicotinic receptors: Function, modulation and structure. Sem. Neurosci. 7:91-101; 1995.
2. 3H]methylcarbamylcholine in rat brain. Eur. J. Pharmacol. 253:261-267; 1994.
3. Arendash, G. W.; Sengstock, G. J.; Sanberg, P. R.; Kem, W. R.: Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res. 674:252-259; 1995.
4. Arneric, S. P.; Sullivan, J. P.; Briggs, C. A.; Donnelly-Roberts, D.; Anderson, D. J.; Raskiewicz, J. L.; Hughes, M. L.; Cadman, E. D.; Adams, P.; Garvey, D. S.; Wasicak, J.; Williams, M.: (S)-3-Methyl-5-(1-Methyl-2-Pyrrolidinyl) Isoxazole (ABT 418): A novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization. J. Pharmacol. Exp. Ther. 270:310-318; 1994.
5. Arneric, S. P.; Sullivan, J. P.; Decker, M. W.; Brioni, J. D.; Bannon, A. W.; Briggs, C. A.; Donnelly-Roberts, D.; Radek, R. J.; Marsh, K. C.; Kyncl, J.; Williams, M.; Buccafusco, J. J.: Potential treatment of Alzheimer's Disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like and cytoprotective properties. Alzheimer Disease and Associated Disorders 9 (Suppl. 2):50-61; 1995.
6. Benowitz, N. L.: Nicotine and coronary heart disease. Trends Cardiovasc. Med. 1:315-321; 1991.
7. Birdsall, N. J. M.; Burgen, A. S. V.; Hulme, E. C.: The binding of agonists to brain muscarinic receptors. Mol. Pharmacol. 14:723-736; 1978.
8. Briggs, C. A.; McKenna, D. G.; Piattoni-Kaplan, M.: Human α7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacology 34:583-590; 1995.
9. Brioni, J. D.; Kim, D. J. B.; Brodie, M. S.; Decker, M. W.; Arneric, S. P.: ABT-418: Discriminative stimulus properties and ventral tegmental cell activity. Psychopharmacology 119:368-375; 1995.
10. Brioni, J. D.; Kim, D. J. B.; O'Neill, A. B.; Williams, J. E. G.; Decker, M. W.: Clozapine attenuates the discriminative stimulus properties of (-)-nicotine. Brain Res. 643:1-9; 1994.
11. Brioni, J. D.; O'Neill, A. B.; Kim, D. J. B.; Decker, M. W.: Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. Eur. J. Pharmacol. 238:1-8; 1993.
12. Brioni, J. D.; O'Neill, A. B.; Kim, D. J. B.; Decker, M. W.; Arneric, S. P.: ABT-418: The anxiolytic and discriminative stimulus properties in rodents. Soc. Neurosci. Abstr. 20:174; 1994.
13. Buccafusco, J. J.; Jackson, W. J.: Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol. Aging 12:233-238; 1991.
14. Bymaster, F. P.; Wong, D. T.; Mitch, C. H.; Ward, J. S.; Calligaro, D. O.; Schoepp, D. D.; Shannon, H. E.; Sheardown, M. J.; Olesen, P. H.; Suzdak, P. D.: Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232). J. Pharmacol. Exp. Ther. 269:282-289; 1994.
15. Chaturvedi, V.; Donnelly-Roberts, D. L.; Lentz, T. L.: Effects of mutations of Torpedo acetylcholine receptor α1 subunit residues 184-200 on α-bungarotoxin binding in a recombinant fusion protein. Biochem. 32:9570-9576; 1993.
16. 50) of an enzymatic reaction. Biochem. Pharmacol. 22:3099-3108; 1973.
17. Clarke, P. B. S.: The fall and rise of neuronal α-bungarotoxin binding proteins. Trends Pharmacol. Sci. 13:407-413; 1992.
18. Coyle, J. T.; Price, D. L.; DeLong, M. R.: Alzheimer's Disease: A disorder of cortical cholinergic innervation. Science 219:1189-1190; 1983.
19. Crismon, M. L.: Tacrine: First drug approved for Alzheimer's Disease. Ann. Pharmacother. 28:744-751; 1994.
20. Cutler, N. R.; Sramek, J. J.: Muscarinic M1 receptor agonists: Potential in the treatment of Alzheimer's Disease. CNS Drugs 3:467-481; 1995.
21. Davis, K. L.; Powchik, P.: Tacrine. Lancet 345:625-630; 1995.
22. 125I-α-bungarotoxin receptor subtypes. Mol. Pharmacol. 47:164-171; 1995.
23. Decker, M. W.; Majchrzak, M. J.; Anderson, D. J.: Effects of nicotine on spatial memory deficits in rats with septal lesions. Brain Res. 572:281-285; 1992.
24. Deneris, E. S.; Connolly, J.; Rogers, S. W.; Duvoisin, R.: Pharmacological and functional diversity of neuronal nicotinic acetylcholine receptors. Trends Pharmacol. Sci. 12:34-40; 1991.
25. Dunnett, S. B.; Fibiger, H. C.: Role of forebrain cholinergic systems in learning and memory: Relevance to the cognitive deficits of aging and Alzheimer's dementia. Prog. Brain Res. 98:413-420; 1993.
26. Enna, S. J.; Snyder, S. H.: Properties of γ-aminobutyric acid receptor binding in rat brain synaptic membrane fractions. Brain Res. 100:81-87; 1975.
27. Flores, C. M.; Rogers, S. W.; Pabreza, L. A.; Wolfe, B. B.; Kellar, K. J.: A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is up-regulated by chronic nicotine treatment. Mol. Pharmacol. 41:31-37; 1992.
28. Gopalakrishnan, M.; Buisson, B.; Touma, E.; Giordano, T.; Campbell, J. E.; Hu, I. C.; Donnelly-Roberts, D.; Arneric, S. P.; Bertrand, D.; Sullivan, J. P.: Stable expression and pharmacological properties of the human α7 nicotinic acetylcholine receptor. Eur. J. Pharmacol. Mol. Pharmacol. 290:237-246; 1995.
29. Gopalakrishnan, M.; Monteggia, L. M.; Anderson, D. J.; Arneric, S. P.; Sullivan, J. P.: Stable expression, pharmacologic properties and regulation of human nicotinic acetylcholine α4β2 receptor. J. Pharmacol. Exp. Ther. 276:289-297; 1995.
30. Hock, F. J.: Therapeutic approaches for memory impairments. Behav. Brain Res. 66:143-150; 1995.
31. Hunter, B. E.; de Fiebre, C. M.; Papke, R. L.; Kem, W. R.; Meyer, E. M.: A novel nicotinic agonist facilitates induction of long-term potentiation in the rat hippocampus. Neurosci. Lett. 168:130-134; 1994.
32. Listerud, M.; Brussaard, A. B.; Devay, P.; Colman, D. R.; Role, L. W.: Functional contribution of neuronal AChR subunits revealed by antisense oligonucleotides. Science 254:1518-1521; 1991.
33. Lukas, R. J.: Expression of ganglia-type nicotinic acetylcholine receptors and nicotinic ligand binding sites by cells of the IMR-32 human neuroblastoma clonal line. J. Pharmacol. Exp. Ther. 265:294-302; 1993.
34. Marks, M. J.; Stitzel, J. A.; Romm, E.; Wehner, J. M.; Collins, A. C.: Nicotinic binding sites in rat and mouse brain: Comparison of acetylcholine, nicotine and α-bungarotoxin. Mol. Pharmacol. 30:427-436; 1986.
35. Martin, E. J.; Panickar, K. S.; King, M. A.; Deyrup, M.; Hunter, B. E.; Wang, G. H.; Meyer, E. M.: Cytoprotective actions of 2,4-dimethoxybenzylidene anabaseine in differentiated PC12 cells and septal cholinergic neurons. Drug Dev. Res. 31:135-141; 1994.
36. McGehee, D. S.; Role, L. W.: Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu. Rev. Physiol. 57:521-546; 1995.
37. Meyer, E. M.; de Fiebre, C. M.; Hunter, B. E.; Simpkins, C. E.; Frauworth, N.; De Fiebre, N. E. C.: Effects of anabaseine-related analogs on rat brain nicotinic receptor binding and on avoidance behaviors. Drug Dev. Res. 31:127-134; 1994.
38. 3H]Cytisine binding to nicotinic cholinergic receptors in brain. Mol. Pharmacol. 39: 9-12; 1991.
39. Papke, R. L.: The kinetic properties of neuronal nicotinic receptors: Genetic basis of functional diversity. Prog. Neurobiol. 41:509-531; 1993.
40. Pellow, S.; Chopin, P.; File, S. E.; Briley, M.: Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Meth. 14:149-167; 1985.
41. Rust, G.; Burgunder, J. -M.; Lauterburg, T. E.; Cachelin, A. B.: Expression of neuronal nicotinic acetylcholine receptor subunit genes in the rat autonomic nervous system. Eur. J. Neurosci. 6:478-485; 1994.
42. Sahakian, B.; Jones, G.; Levy, R.; Gray, J.; Warburton, D.: The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br. J. Psychiatry 154:797-800; 1989.
43. Sargent, P. B.: The diversity of neuronal nicotinic acetylcholine receptors. Annu. Rev. Neurosci. 16:403-443; 1993.
44. Shannon, H. E.; Bymaster, F. P.; Calligaro, D. O.; Greenwood, B.; Mitch, C. H.; Sawyer, B. D.; Ward, J. S.; Wong, D. T.; Olesen, P. H.; Sheardown, M. J.: Xanomeline: A novel muscarinic receptor agonist with functional selectivity for M1 receptors. J. Pharmacol. Exp. Ther. 269:271-281; 1994.
45. Spencer, D. G.; Emmett-Oglesby, M. W.:Parallel processing strategies in th eapplication of microcomputers to the behavioral laboratory. Behav. Res. Meth. Instrument. 17:294-300; 1985.
46. Stolerman, I. P.; Mirza, N. R.; Shoaib, M.: Nicotine psychopharmacology: Addiction, cognition and neuroadaptation. Med. Res. Rev. 15:47-72; 1995.
47. Séguéla, P.; Wadiche, J.; Dineley-Miller, K.; Dani, J. A.; Patrick, J. W.: Molecular cloning, functional properties, and distribution of rat brain α7: A nicotinic cation channel highly permeable to calcium. J. Neurosci. 13:596-604; 1993.
48. Terry, A. V., Jr.; Buccafusco, J. J.; Jackson, W. J.: Scopolamine reversal of nicotine enhanced delayed matching-to-sample performance in monkeys. Pharmacol. Biochem. Behav. 45:925-929; 1993.
49. Whitehouse, P. J.; Price, D. L.; Clark, A. W.; Coyle, J. T.; DeLong, M. R.: Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 10:122-126; 1981.
50. Woodruff-Pak, D. S.; Li, Y.-T.; Kem, W. R.: A nicotinic agonist (GTS-21), eyeblink classical conditioning, and nicotinic receptor binding in rabbit brain. Brain Res. 645:309-317; 1994.
51. Zoltewicz, J. A.; Prokai-Tatrai, K.; Bloom, L. B.; Kem, W. R.: Long range transmission of polar effects in cholinergic 3-arylidene anabaseines. Conformations calculated by molecular modelling. Heterocycles 35:171-179; 1993.